Evaluation of Microspheres Containing Cytokine Neutralizing Antibodies in Endotoxemia

REFERENCES

• Marcus C. S., Kuperus J. H., Butler J. A., Henneman P. L., Salk R. D., Chen B. Y., Vivian M. R. P., Yamanaka L. M. Phagocytic labelling of leukocytes with 99m Tc-albumin colloid for nuclear imaging. Nucl. Med. Biol. 1988; 15: 673–682
   Web of Science ®Google Scholar
• Rhodes B. A., Zolle I., Buchanan J. W., et al. Radioactive albumin microspheres for studies of the pulmonary circulation. Radiology 1969; 92: 1453–1460
   PubMed Web of Science ®Google Scholar
• Zolle I., Rhodes B. A., Wagner H. N. Preparation of metabolizable radioactive human serum albumin microspheres for studies of the circulation. Int. J. Appl. Radiat. Isot. 1970; 21: 155–167
   PubMedGoogle Scholar
• Bender A., Schafer V., Steffan A. M., Royer C., Kreuter J., Rubsamen-Waigmann H., von Briesen H. Inhibition of HIV in vitro by antiviral drug-targeting using nanoparticles. Res. Virol. 1994; 145: 215–220
   PubMedGoogle Scholar
• Gerber D. A., Oettinger C. W., D'Souza M. J., Milton G. V., Larsen C. P., Pearson T. C. Prolongation of murine cardiac allograft survival by microspheres containing TNFα and IL-1β neutralizing antibodies. J. Drug Targeting 1995; 3: 311–315
   PubMed Web of Science ®Google Scholar
• Sah H., Toddywala R., Chien Y. W. Continuous release of proteins from biodegradable microcapsules and in vivo re-evaluation of their potential as a vaccine adjuvant. J. Controlled Release 1995; 35: 137–144
   Web of Science ®Google Scholar
• Saha G. B., Feiglin D. H. I., O'Donnell J. K., Go R. T., Karam P. M., Macintyre W. Experience with Technetium-99m albumin colloid kit for reticuloendothelial system imaging. Radiopharmacy 1986; 14: 149–151
   Google Scholar
• Melissen P. M. B., van Vianen W., Bidjai O., van Marion M., Bakker-Wouddenberg I. A. J. M. Free and liposome-encapsulated muramyl tripeptide phosphidylethanolamine (MTPPE) and interferon-γ in experimental infection with Listeria monocytogenes. Biotherapy 1993; 6: 113–124
   PubMedGoogle Scholar
• Hockertz S., Franke G., Paulini I., Lohmann-Matthes M. L. Immunotherapy of murine visceral Leishmaniasis with murine recombinant interferon-γ and MTP-PE encapsulated in liposomes. J. Interferon Res. 1991; 11: 177–185
   PubMedGoogle Scholar
• Saravolac E. G., Kournikakis B., Gorton L., Wong J. P. Effect of liposome-encapsulation on immunomodulating and antiviral activities of interferon-γ. Antiviral Res. 1996; 29: 199–207
   PubMed Web of Science ®Google Scholar
• Dinarello C. A., Cannon J. G., Wolf S. M., Bernheim H. A., Beutler B., Cerami A., Figari I. S., Palladino M. A., O'Connor J. V. Tumor necrosis factor is an endogenous pyrogen and induces production of interleukin 1. J. Exp. Med. 1986; 163: 1433
   PubMed Web of Science ®Google Scholar
• Cannon J. G., Tompkins R. G., Gelfand J. A., Michie H. R., Stanford G. C., van der Meer J. W. M., Endres S., Lonnemann G., Corsetti J., Chernow B., Wilmore D. W., Wolff S. M., Burke J. F., Dinarello C. A. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J. Infect. Dis. 1990; 161: 79
   PubMed Web of Science ®Google Scholar
• Cerami A., Ikeda Y., Le Trang N., Hotez P. J., Beutler B. Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: The role of cachectin (tumor necrosis factor). Immunol. Lett. 1985; 11: 173
   PubMed Web of Science ®Google Scholar
• Emerson T. E., Lindsey D. C., Jr., Jesmok G. J., Duerr M. L., Fournel M. A. Efficacy of monoclonal antibody against tumor necrosis factor alpha in an endotoxemic baboon model. Circ. Shock 1992; 38: 75–84
   PubMedGoogle Scholar
• van der Poll T., Levi M., van Deventer S. J. H., ten Carte H., Haagmans B. L., Beimond B. J., Buller H. R., Hack C. E., ten Carte J. W. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory response in experimental endotoxemia in chimpanzees. Blood 1994; 83: 446–451
   PubMed Web of Science ®Google Scholar
• Ohlsson K., Bjork P., Bergenfeldt M., Hageman R., Thompson R. C. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348: 550–552
   PubMed Web of Science ®Google Scholar
• Wakabayashi G., Gelfand J. A., Burke J. F., Thompson R. C., Dinarello C. A. A specific receptor antagonist to interleukin1 improves survival after lethal endotoxemia in mice. FASEB J. 1991; 5: 338–343
   PubMed Web of Science ®Google Scholar
• Alexander H. R., Doherty G. M., Buresh C. M., Venzon D. J., Norton J. A. A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J. Exp. Med. 1991; 173: 1029–1032
   PubMed Web of Science ®Google Scholar
• Pourfarzib R., Gajjar D., Riadi I., Oliver J., D'Souza M. J. Enzyme linked immunosorbent assay for detection of human tumor necrosis factor alpha. Pharm. Res. 1993; 10: S–400
   Google Scholar
• Pourfarzib R., Gajjar D., Riadi I., Oliver J., D'Souza M. J. Enzyme linked immunosorbent assay for detection of human interleukin-1beta. Pharm. Res. 1993; 10: S–400
   Google Scholar
• Oliver J. C., Bland L. A., Oettinger C. W., Arduino M. J., McAllister S. K., Aguero S. M., Favero M. S. Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge. Lymphokine Cytokine Res. 1993; 12: 115–120
   PubMedGoogle Scholar
• Mattsson E., Van Dijk H., Van Kessel K., Verhoef J., Fleer A., Rollof J. Intracellular pathways involved in tumor necrosis factor-α release by human monocytes on stimulation with lipopolysaccharide or staphylococcal peptidoglycan are partly similar. J. Infect. Dis. 1996; 173: 212–218
   PubMed Web of Science ®Google Scholar
• Willeaume V., Kruys V., Mijatovic T., Huez G. Tumor necrosis factor-α production induced by viruses and by lipopolysaccharides in macrophages: Similarities and differences. J. Inflammation 1996; 46: 1–12
   Google Scholar
• Hesse D. G., Tracey K. J., Fong Y., Manogue K. R., Palladino M. A., Cerami A., Shires G. T., Lowry S. F. Cytokine appearance in human endotoxemia and primate bacteremia. Surg. Gynecol. Obstet. 1988; 166: 147–153
   PubMedGoogle Scholar
• Netea M. G., Blok W. L., Kullberg B.-J., Bemelmans M., Vogels M. T. E., Buurman W. A., van der Meer J. W. M. Pharmacologic inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice. J. Infect. Dis. 1995; 171: 393–399
   PubMed Web of Science ®Google Scholar
• Russell D. A., Tucker K. K., Chinookoswong N., Thompson R. C., Kohno T. Combined inhibition of interleukin-1 and tumor necrosis factor in rodent endotoxemia: Improved survival and organ function. J. Infect. Dis. 1995; 171: 1528–1538
   PubMed Web of Science ®Google Scholar
• Saravolatz L. D., Wherry J. C., Spooner C., Markowitz N., Allred R., Remick D., Fournel M., Pennington E. Clinical safety, tolerability, and pharmacokinetics of murine monoclonal antibody to human tumor necrosis factor-α. J. Infect. Dis. 1994; 169: 214–217
   PubMed Web of Science ®Google Scholar
• D'Souza M. J., DeSouza P. Site specific microencapsulated drug targeting strategies—liver and gastro-intestinal tract targeting. Adv. Drug Delivery Rev. 1995; 17: 247–254
   Web of Science ®Google Scholar
• de Caestecker M. P., Telfer B. A., Hutchinson I. V., Ballardie F. W. The detection of intracytoplasmic interleukin-α, interleukin-β and tumor necrosis factor α expression in human monocytes using two colour immunofluorescence flow cytometry. J. Immunol. Meth. 1992; 154: 11–20
   PubMed Web of Science ®Google Scholar